Some tickers go quiet for a simple reason: the company behind them has effectively ceased to operate. That is the story of Pure Global Cannabis Inc. (OTC:PRCNF), a Canadian cannabis producer that collapsed into creditor protection more than six years ago.
Petros Pharmaceuticals, Inc (OTC:PTPI) is the kind of sub-penny stock where sharp percentage swings say more about a thin share count and low liquidity than about company fundamentals. Once a Nasdaq-listed men's-health specialist, Petros wasDelistedin 2025, completed a 1-for-25 reverse stock split, and now …
● Provectus is a clinical-stage biotechnology company founded in 2002 and built around its proprietary small molecule rose bengal sodium.
The Praxsyn Corporation (OTC:PXYN) once built aBusinessaround compounded, non-narcotic pain creams aimed at California's workers'-compensation system. Today its stock trades at a fraction of a cent with a market value in the hundreds of dollars and no confirmed catalyst, a familiar profile among dormant …
A Form 4 filed on September 10, 2026, discloses that Kenneth J. Krieg, a director of Leonardo DRS, Inc. (NASDAQ:DRS), disposed of 3,700 shares of common stock on September 9, 2026, via a gift transaction at a price of $0.
Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp, filed a Form 4 on September 10, 2026, disclosing the sale of common stock on September 8, 2026, in connection with the vesting of Restricted Stock Units.
Nicholas Pfeiffer, Corporate Controller of FMC Corp (NYSE:FMC), filed a Form 4 on September 10, 2026, disclosing the sale of 1,251 shares of FMC common stock on September 9, 2026.
Paula Green, SVP of Human Resources at Twist Bioscience Corp, filed a Form 4 on September 10, 2026, reporting the sale of 907 shares of common stock on September 8, 2026, to satisfy tax withholding obligations tied to the vesting of Restricted Stock Units.
Dennis Cho, Senior Vice President, Chief Legal Officer and Corporate Secretary of Twist Bioscience Corp (NASDAQ:TWST), filed a Form 4 on September 10, 2026, reporting a sale of 412 shares of common stock on September 8, 2026, to cover tax withholding obligations tied to …
Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc., filed a statement of changes in beneficial ownership on September 10, 2026, reporting the sale of common stock executed the prior day under a pre-established trading plan.